Process for making 3-pentenenitrile by hydrocyanation of butadiene

Information

  • Patent Grant
  • 7880028
  • Patent Number
    7,880,028
  • Date Filed
    Thursday, July 12, 2007
    16 years ago
  • Date Issued
    Tuesday, February 1, 2011
    13 years ago
Abstract
The invention provides a continuous process for the production of 3-pentenenitrile, comprising: (a) contacting, in a reaction zone, a hydrogen cyanide-containing feed, a 1,3-butadiene-containing feed, and a catalyst precursor composition, wherein the catalyst precursor composition comprises a zero-valent nickel and at least one multidentate phosphorus-containing ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, a phosphine, and a mixed phosphorus-containing ligand or a combination of such members; and(b) maintaining a residence time sufficient to convert about 95% or more of the hydrogen cyanide and to produce a reaction mixture comprising 3-pentenenitrile and 2-methyl-3-butenenitrile, wherein the 2-methyl-3-butenenitrile concentration is maintained below about 15 weight percent of the total mass of the reaction mixture.
Description
FIELD OF THE INVENTION

The invention relates to the hydrocyanation of 1,3-butadiene to produce 3-pentenenitriles and other unsaturated nitrites. More particularly, this invention relates to a process for the hydrocyanation of 1,3-butadiene using a catalyst precursor composition comprising a zero-valent nickel and at least one multidentate phosphorus-containing ligand.


BACKGROUND OF THE INVENTION

3-Pentenenitrile (3PN) is an important intermediate in the production of adiponitrile (ADN). ADN is of particular interest because it is a commercially versatile and important intermediate in the industrial production of nylon polyamides useful in forming films, fibers, and molded articles.


It is well known in the art that 3PN may be formed through a series of reactions as illustrated in Equations 1 and 2 below,




embedded image



wherein BD is butadiene, HCN is hydrogen cyanide, and 2M3BN is the BD hydrocyanation co-product 2-methyl-3-butenenitrile. U.S. Pat. No. 3,496,215 describes the catalytic hydrocyanation of BD (equation 1) in the presence of NiL4 complexes wherein L is a monodentate phosphorus containing ligand. The relative amounts of 3PN and 2M3BN can be dependent upon the catalyst utilized in this chemical reaction. U.S. Pat. No. 3,536,748 describes the catalytic isomerization of 2M3BN to 3PN (equation 2) in the presence of NiL4 complexes.


U.S. Pat. No. 3,536,748 discloses that in the presence of HCN, the nickel complex preferentially catalyzes formation of undesired, six-carbon, saturated dinitrile (2-methylglutaronitrile, MGN) from 2M3BN (see equation 3 below). This patent notes that, because of the overriding competitive hydrocyanation reaction, for the isomerization of 2M3BN to 3PN it is necessary to avoid the presence of large amounts of HCN, for example any amount of the order of or in excess of 1:1 mole ratio with the 2M3BN starting material. The reference further discloses that HCN has no significant effect per se on the isomerization reaction, its presence in minor amounts in the starting material can be tolerated if necessary, and the isomerization process is preferably conducted in the absence of HCN.




embedded image


U.S. Pat. No. 6,169,198 discloses that hydrocyanation of BD to prepare ADN can generally be divided into three steps. The first is synthesis of mononitriles by hydrocyanation of BD (as in Equation 1 above), for which the selectivity for the linear 3PN is about 70% or less, depending on the catalyst used. The second is isomerization of the 2M3BN present in the mixtures to 3PN (as in Equation 2 above) and isomerization of 3PN to various n-pentenenitriles; the third is synthesis of dinitriles. Also disclosed is a preferred embodiment in which the ratio of the amounts of 3PN to 2M3BN obtained in the monoaddition of HCN onto the BD-containing hydrocarbon mixture is at least 5:1, preferably at least 10:1, in particular at least 20:1, with a catalyst comprising at least one metallocene-phosphorus(III)-nickel(0) complex. The reference further discloses that it is generally possible to dispense with division of the process for preparing ADN into the three steps of monoaddition of HCN onto a BD-containing hydrocarbon mixture; isomerization; addition of HCN onto 4-pentenenitrile (4PN) formed in situ; and the addition of 2 mole equivalents of HCN onto a BD-containing hydrocarbon mixture can be designed as a one-stage process.


In recent years, a new class of catalysts has been described for the transformations of Equations 1 and 2. U.S. Pat. Nos. 5,512,695; 5,512,696; 5,523,453; 5,663,369; 5,688,986; 5,693,843; 5,723,641; 5,821,378; 5,959,135; 5,981,772; 6,020,516; 6,127,567; 6,171,996; 6,171,997; and WO99/52632 describe the use of diphosphite and diphosphinite nickel complexes as catalysts for the hydrocyanation of BD or 3PN and the isomerization of 2M3BN to 3PN. In general, this class of catalysts is characterized by greater catalytic activity and resistance to HCN-derived degradation reactions compared to the catalysts comprising nickel complexes of monodentate phosphites and phosphinites. As a result, this new class of catalysts may generally be used effectively at much lower concentrations and over a broader range of reaction conditions. U.S. Pat. Nos. 5,821,378; 5,981,772 and 6,020,516 describe the capability of a limited number of these catalyst systems to isomerize 2M3BN at the same temperature at which BD is hydrocyanated.


It would be desirable to have a high yield 3PN process in which BD hydrocyanation and 2M3BN isomerization occur concurrently in the same reaction zone. Such a combined BD hydrocyanation/2M3BN isomerization process would have fewer reaction and process separation steps than a process in which the hydrocyanation and isomerization reactions were performed, for example, in separate reaction zones under reaction conditions optimized independently for BD hydrocyanation or for 2M3BN isomerization to 3PN. The advantages of a combined BD hydrocyanation/2M3BN isomerization process having simplified process complexity could include reduced capital investment and reduced cost of manufacture. Reduced yield loss to undesired by-products, such as MGN and compounds derived from BD dimerization and/or oligomerization, might also be realized with a combined BD hydrocyanation/2M3BN isomerization process.


SUMMARY OF THE INVENTION

In a first aspect, the present invention can provide a process for the continuous production of 3-pentenenitrile, comprising: (a) contacting, in a reaction zone, a hydrogen cyanide (HCN)-containing feed, a butadiene (BD)-containing feed, and a catalyst precursor composition, wherein the catalyst precursor composition comprises a zero-valent nickel and at least one multidentate phosphorus-containing ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, a phosphine, and a mixed phosphorus-containing ligand or a combination of such members; and (b) maintaining a residence time in the reaction zone sufficient to convert about 95% or more of the hydrogen cyanide and to produce a reaction mixture comprising 3-pentenenitrile and 2-methyl-3-butenenitrile, wherein the 2-methyl-3-butenenitrile concentration is maintained below about 15 weight percent of the total mass of the reaction mixture.


Another aspect of the present invention is the process wherein the molar ratio of the hydrogen cyanide in the feed to the butadiene in the feed is in the range of about 0.90:1.00 to about 1.04:1.00, and the molar ratio of the zero-valent nickel in the feed to the butadiene in the feed is in the range of about 0.00005:1.00 to about 0.0050:1.00.


Another aspect of the present invention is the process wherein the temperature is maintained within a range of about 80° C. to about 140° C.


Another aspect of the present invention is the process wherein the temperature is maintained within the range of about 100° C. to about 130° C.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a phosphite.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a phosphonite.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a phosphinite.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a phosphine.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a mixed phosphorus-containing ligand comprising at least one combination selected from the group consisting of a phosphite-phosphonite, a phosphite-phosphinite, a phosphite-phosphine, a phosphonite-phosphinite, a phosphonite-phosphine, and a phosphinite-phosphine or a combination of such members.


Another aspect of the present invention is the process wherein the molar ratio of the hydrogen cyanide in the feed to the butadiene in the feed is in the range of about 0.92:1.00 to about 0.98:1.00.


Another aspect of the present invention is the process wherein the molar ratio of the zero-valent nickel in the feed to the butadiene in the feed is in the range of about 0.0001:1.00 to about 0.0010:1.00.


Another aspect of the present invention is the process wherein the residence time is sufficient to maintain the 2-methyl-3-butenenitrile concentration at or below about 10 wt % of the total mass of the reaction mixture.


Another aspect of the present invention is the process further comprising optionally contacting a feed comprising 2-methyl-3-butenenitrile in the reactor.


Another aspect of the present invention is the process wherein the catalyst precursor composition further comprises at least one monodentate phosphorus-containing ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, and a phosphine or a combination of such members.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a bidentate phosphite.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a bidentate phosphonite.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a bidentate phosphinite.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a bidentate phosphine.


Another aspect of the present invention is the process wherein the multidentate phosphorus-containing ligand is a bidentate mixed phosphorus-containing ligand selected from the group consisting of a phosphite-phosphonite, a phosphite-phosphinite, a phosphite-phosphine, a phosphonite-phosphinite, a phosphonite-phosphine, and a phosphinite-phosphine or a combination of such members.







DETAILED DESCRIPTION OF THE INVENTION

The invention provides a process for the continuous production of 3-pentenenitrile in which a HCN-containing feed, a BD-containing feed, and a catalyst precursor composition solution are contacted, for example concurrently, in a reaction zone, for example a continuous-stirred-tank-reactor (CSTR), and a residence time is maintained sufficient to convert about 95% or more of the HCN and to produce a reaction mixture comprising 3PN and 2M3BN, wherein the 2M3BN concentration is maintained below about 15 weight percent of the total mass of the reaction mixture.


In another aspect, the process of the invention further comprises optionally contacting a feed comprising 2M3BN in the reaction zone. The 2M3BN in the feed can be produced by a different process or prepared in a separate manufacturing facility. Alternatively, the 2M3BNin the feed may be obtained from a BD hydrocyanation and/or 2M3BN isomerization process as described in the art or the process of the current invention wherein a stream comprising 2M3BN may be, for example, distilled from a higher boiling reaction product comprising 3PN. Such a stream comprising 2M3BN can be recycled to the reaction zone of the present invention in which BD hydrocyanation and 2M3BN isomerization occurs. Potential advantages of such a process can include the elimination of investment and of the associated variable and fixed costs for operating an additional 2M3BN isomerization reaction vessel, distillation columns, and the associated pumps, heat exchangers, piping, and control instrumentation.


In processes falling within the scope of the present invention, the hydrocyanation and isomerization reactions of Equations 1 and 2 (above) can be carried out concurrently and continuously in the same reaction zone, for example under high BD and HCN conversion conditions.


The catalyst precursor composition comprises a zero-valent nickel and at least one multidentate phosphorus-containing (P-containing) ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, a phosphine, and a mixed P-containing ligand or a combination of such members. As used herein, the term “mixed P-containing ligand” means a multidentate phosphorus-containing ligand comprising at least one combination selected from the group consisting of a phosphite-phosphonite, a phosphite-phosphinite, a phosphite-phosphine, a phosphonite-phosphinite, a phosphonite-phosphine, and a phosphinite-phosphine or a combination of such members.


The catalyst precursor compositions may further comprise at least one monodentate P-containing ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, and a phosphine or a combination of such members, provided that the monodentate P-containing ligand does not detract from the beneficial aspects of the invention. The monodentate P-containing ligand may be present as an impurity from the synthesis of the multidentate P-containing ligand, or the monodentate P-containing ligand may be added as an additional component of the catalyst precursor composition.


Each catalyst precursor composition useful in the present invention may be considered a “precursor” composition in that the zero-valent nickel at some point becomes bound to at least one multidentate P-containing ligand, and further in all likelihood, additional reactions occur during hydrocyanation, such as, for example, complexing of the initial catalyst composition to an ethylenically unsaturated compound.


As used herein, the term “catalyst precursor composition” also includes within its meaning recycled catalyst, that is, a catalyst precursor composition comprising a zero-valent nickel and at least one multidentate P-containing ligand which, having been used in the process of the invention, is returned or may be returned to the process and used again.


The term “hydrocarbyl” is well known in the art and designates a hydrocarbon molecule from which at least one hydrogen atom has been removed. Such molecules can contain single, double, or triple bonds.


The term “aryl” is well-known in the art and designates an aromatic hydrocarbon molecule from which at least one hydrogen atom has been removed.


Examples of suitable aryl groups include those containing 6 to 10 carbon atoms, which can be unsubstituted or singly or multiply substituted. Suitable substituents include, for example, C1-C4 hydrocarbyl, or halogen such as fluorine, chlorine or bromine, or halogenated hydrocarbyl such a trifluoromethyl, or aryl such as phenyl.


The P-containing ligand may be multidentate, for example bidentate, or tridentate. The P-containing ligand may be selected from the group consisting of a phosphite, a phosphonite, a phosphinite, a phosphine, and a mixed P-containing ligand or a combination of such members. The multidentate P-containing ligand may be represented by Formula I




embedded image


wherein


X11, X12, X13, X21, X22, X23 independently represent oxygen or a single bond,


R11, R12 independently represent identical or different, single or bridged organic radicals,


R21, R22 independently represent identical or different, single or bridged organic radicals, and


Y represents a bridging group.


It is to be understood that Formula I may represent a single compound or a mixture of different compounds having the indicated structure.


In one embodiment, all of the groups X11, X12, X13, X21, X22, X23 may represent oxygen. In such a case, the bridging group Y is joined to phosphite groups. In such a case, the multidentate P-containing ligand represented by Formula I is a phosphite.


In another embodiment, X11 and X12 may each represent oxygen, and X13, a single bond; or X11 and X13 may each represent oxygen and X12, a single bond, so that the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphonite. In such a case, X21, X22, and X23 may each represent oxygen, so that the phosphorus atom surrounded by X21, X22, and X23 may be the central atom of a phosphite; or X21 and X22 may each represent oxygen and X23, a single bond; or X21 and X23 may each represent oxygen and X22, a single bond, so that the phosphorus atom surrounded by X21, X22, and X23 may be the central atom of a phosphonite; or X23 may represent oxygen and X21 and X22, each a single bond; or X21 may represent oxygen and X22 and X23, each a single bond, so that the phosphorus atom surrounded by X21, X22, and X23 may be the central atom of a phosphinite; or X21, X22, and X23 may each represent a single bond, so that the phosphorus atom surrounded by X21, X22, and X23 may be the central atom of a phosphine.


When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphonite and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphite, the multidentate ligand represented by Formula I is a phosphite-phosphonite and is an example of a mixed P-containing ligand. When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphonite and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphonite, the multidentate P-containing ligand represented by Formula I is a phosphonite. When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphonite and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphinite, the multidentate P-containing ligand represented by Formula I is a phosphonite-phosphinite and is an example of a mixed P-containing ligand. When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphonite and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphine, the multidentate P-containing ligand represented by Formula I is a phosphonite-phosphine and is an example of a mixed P-containing ligand.


In another embodiment, X13 may represent oxygen and X11 and X12, each a single bond; or X11 may represent oxygen and X12 and X13, each a single bond, so that the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphinite. In such a case, X21, X22, and X23 may each represent oxygen, so that the phosphorus atom surrounded by X21, X22, and X23 may be the central atom of a phosphite; or X23 may represent oxygen and X21 and X22, each a single bond; or X21 may represent oxygen and X22 and X23, each a single bond, so that the phosphorus atom surrounded by X21, X22, and X23 may be the central atom of a phosphinite; or X21, X22, and X23 may each represent a single bond, so that the phosphorus atom surrounded by X21, X22, and X23 may be the central atom of a phosphine.


When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphinite and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphite, the multidentate P-containing ligand represented by Formula I is a phosphite-phosphinite and is an example of a mixed P-containing ligand. When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphinite and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphinite, the multidentate P-containing ligand represented by Formula I is a phosphinite. When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphinite and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphine, the multidentate P-containing ligand represented by Formula I is a phosphinite-phosphine and is an example of a mixed P-containing ligand.


In another embodiment, X11, X12, and X13 may each represent a single bond, so that the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphine. In such a case, X21, X22, and X23 may each represent oxygen, so that the phosphorus atom surrounded by X21, X22, and X23 may be the central atom of a phosphite; or X21, X22, and X23 may each represent a single bond, so that the phosphorus atom surrounded by X21, X22 , and X23 may be the central atom of a phosphine.


When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphine and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphite, the multidentate P-containing ligand represented by Formula I is a phosphite-phosphine and is an example of a mixed P-containing ligand. When the phosphorus atom surrounded by X11, X12, and X13 is the central atom of a phosphine and the phosphorus atom surrounded by X21, X22, and X23 is the central atom of a phosphine, the multidentate P-containing ligand represented by Formula I is a phosphine.


Bridging group Y may be aryl groups substituted, for example, with C1-C4 hydrocarbyl, or halogen such as fluorine, chlorine, or bromine, or halogenated hydrocarbyl such as trifluoromethyl, or aryl such as phenyl, or unsubstituted aryl groups, for example those with 6 to 20 carbon atoms in the aromatic system, for example 2,2′-biphenyl and 1,1′-bi-2-naphthyl.


Radicals R11 and R12 may independently represent identical or different organic radicals. R11 and R12 may be aryl radicals, for example those containing 6 to 10 carbon atoms, which can be unsubstituted or singly or multiply substituted, for example by C1-C4 hydrocarbyl, or halogen such as fluorine, chlorine, or bromine, or halogenated hydrocarbyl such as trifluoromethyl, or aryl such as phenyl, or unsubstituted aryl groups.


Radicals R21 and R22 may independently represent identical or different organic radicals. R21 and R22 may be aryl radicals, for example those containing 6 to 10 carbon atoms, which can be unsubstituted or singly or multiply substituted, for example by C1-C4 hydrocarbyl, or halogen such as fluorine, chlorine, or bromine, or halogenated hydrocarbyl such as trifluoromethyl, or aryl such as phenyl, or unsubstituted aryl groups.


Radicals R11 and R12 may be single or bridged. Radicals R21 and R22 may also be single or bridged. Radicals R11, R12, R21, and R22 may all be single, or two may be bridged and two single, or all four may be bridged in the manner described.


Examples of multidentate P-containing ligands include the following:

    • 1) the compounds of Formula I, II, III, IV, and V disclosed in U.S. Pat. No. 5,723,641;
    • 2) the compounds of Formula I, II, III, IV, V, VI, and VII disclosed in U.S. Pat. No. 5,512,696, for example the compounds used in Examples 1 through 31 therein;
    • 3) the compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV disclosed in U.S. Pat. No. 5,821,378, for example the compounds used in Examples 1 through 73 therein;
    • 4) the compounds of Formula I, II, III, IV, V, and VI disclosed in U.S. Pat. No. 5,512,695, for example the compounds used in Examples 1 through 6 therein;
    • 5) the compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, and XIV disclosed in U.S. Pat. No. 5,981,772, for example the compounds used in Examples 1 through 66 therein;
    • 6) the compounds disclosed in U.S. Pat. No. 6,127,567, for example the compounds used in Examples 1 through 29 therein;
    • 7) the compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, and X disclosed in U.S. Pat. No. 6,020,516, for example the compounds used in Examples 1 through 33 therein;
    • 8) the compounds disclosed in U.S. Pat. No. 5,959,135, for example the compounds used in Examples 1 through 13 therein;
    • 9) the compounds of Formula I, II, and III disclosed in U.S. Pat. No. 5,847,191;
    • 10) the compounds disclosed in U.S. Pat. No. 5,523,453, for example the compounds of Formula 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 therein;
    • 11) the compounds disclosed in U.S. Pat. No. 5,693,843, for example the compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, and XIII, for example the compounds used in Examples 1 through 20 therein;
    • 12) the compounds of Formula V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, and XXVI disclosed in U.S. Pat. No. 6,893,996;
    • 13) the compounds disclosed in published patent application WO 01/14392, for example the compounds illustrated in Formula V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XXI, XXII, and XXIII therein;
    • 14) the chelating compounds disclosed in U.S. Pat. No. 6,242,633, for example the compounds of Formula If, Ig, and Ih;
    • 15) the compounds disclosed in U.S. Pat. No. 6,521,778, for example the compounds of Formula I, Ia, Ib, and Ic, for example the compounds referred to as Ligand I and II;
    • 16) the compounds disclosed in published patent application WO 02/13964, for example the compounds of Formula Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, and Ik, for example the compounds referred to as Ligand 1, 2, 3, 4, 5, and 6;
    • 17) the compounds disclosed in German Patent Application DE 100 460 25;
    • 18) the chelating compounds disclosed in U.S. Pat. No. 7,022,866, for example the compounds of Formula 1 and 2, for example the compounds referred to as Ligand 1 and 2;
    • 19) the compounds disclosed in United States Published Patent Application No. 2005/0090677, for example the compounds of Formula 1, 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, 1i, 1j, 1k, 11, 1m, 1n, 1o, 2, and 3;
    • 20) the compounds disclosed in United States Published Patent Application No. 2005/0090678, for example the compounds of Formula 1 and 2, for example the compounds referred to as Ligand 1, 2, 3, 4, 5, and 6;
    • 21) the compounds disclosed in published patent application WO 2005/042547, for example the compounds of Formula 1, 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, 1i, 1j, 1k, 1l, 1m, 1n, 1o, 2, 3, 4, 5, and 6, for example the compounds referred to as Ligand 1, 2, 3, and 4;
    • 22) the chelating compounds disclosed in U.S. Pat. No. 6,169,198, for example the compounds of Formula I; and
    • 23) the compounds disclosed in U.S. Pat. No. 6,660,877, for example the compounds of Formula I, II, and III, for example the compounds used in Examples 1 through 25 therein.


      These references also disclose methods for preparing multidentate ligands of Formula I.


Further examples of the multidentate P-containing ligand include a bidentate phosphite ligand selected from a member of the group represented by Formulas II and III, in which all like reference characters have the same meaning, except as further explicitly limited:




embedded image


wherein R1 and R5 are independently selected from the group consisting of C1 to C5 hydrocarbyl, and R2, R3, R4, R6, R7 and R8 are independently selected from the group consisting of H and C1 to C4 hydrocarbyl.


It will be recognized that Formula II and Formula III are two dimensional representations of three-dimensional molecules and that rotation about chemical bonds can occur in the molecules to give configurations differing from those shown. For example, rotation about the carbon-carbon bond between the 2- and 2′-positions of the biphenyl and octahydrobinaphthyl bridging groups of Formula II and Formula III, respectively, can bring the two phosphorus atoms of each Formula in closer proximity to one another and can allow the phosphite ligand to bind to a single nickel atom in a bidentate fashion. The term “bidentate” is well known in the art and means both phosphorus atoms of the ligand are bonded to a single nickel atom.


For example, the multidentate P-containing ligand can be selected from a member of the group represented by Formulas II and III, wherein


R1 is methyl, ethyl, isopropyl or cyclopentyl;


R2 is H or methyl;


R3 is H or a C1 to C4 hydrocarbyl;


R4 is H or methyl;


R5 is methyl, ethyl or isopropyl; and


R6, R7 and R8 are independently selected from the group consisting of H and C1 to C4 hydrocarbyl.


As additional examples, the multidentate P-containing ligand can be selected from a member of the group represented by Formula II, wherein


R1, R4, and R5 are methyl;


R2, R6, R7 and R8 are H; and


R3 is a C1 to C4 hydrocarbyl;


or


R1 is isopropyl;


R2 is H;


R3 is a C1 to C4 hydrocarbyl;


R4 is H or methyl;


R5 is methyl or ethyl;


R6 and R8 are H or methyl; and


R7 is H, methyl or tertiary-butyl;


or the multidentate P-containing ligand can be selected from a member of the group represented by Formula III, wherein


R1 is isopropyl or cyclopentyl;


R5 is methyl or isopropyl; and


R6, R7, and R8 are H.


As yet another example, the multidentate P-containing ligand can be represented by Formula II, wherein R1 is isopropyl; R2, R6, and R8 are H; and R3, R4, R5, and R7 are methyl.


The multidentate P-containing ligand may also be a polymeric ligand composition, as disclosed, for example, in U.S. Pat. Nos. 6,284,865; 6,924,345, or United States Published Patent Application No. 2003/135014. Methods for preparing such polymeric ligand compositions are well known in the art and are disclosed, for example, in the above cited references.


The catalyst precursor compositions may further comprise at least one monodentate P-containing ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, and a phosphine or a combination of such members. The monodentate P-containing ligand may be added as an additional component of the catalyst precursor composition, or it may be present, for example, as an impurity from the synthesis of the multidentate P-containing ligand. The monodentate P-containing ligand may be represented by Formula IV

P(X1R31)(X2R32)(X3R33)   Formula IV


wherein


X1, X2, X3 independently represent oxygen or a single bond, and


R31, R32, R33 independently represent identical or different, single or bridged organic radicals.


It is to be understood that Formula IV may be a single compound or a mixture of different compounds having the indicated structure.


In one embodiment, all of the groups X1, X2, and X3 may represent oxygen, so that Formula IV represents a phosphite of formula P(OR31)(OR32)(OR33), wherein R31, R32, and R33 have the meanings defined herein.


If one of the groups X1, X2, and X3 represents a single bond and two groups represent oxygen, Formula IV represents a phosphonite of formula P(OR31)(OR32)(R33), P(R31)(OR32)(OR33), or P(OR31)(R32)(OR 33), wherein R31, R32, and R33 have the meanings defined herein.


If two of the groups X1, X2, and X3 represent single bonds and one group represents oxygen, Formula IV represents a phosphinite of formula P(OR31)(R32)(R33) or P(R31)(OR32)(R33) or P(R31)(R32)(OR33), wherein R31, R32, and R33 have the meanings defined herein.


The groups X1, X2, X3 may independently represent oxygen or a single bond. If all the groups X1, X2, and X3 represent single bonds, Formula IV represents a phosphine of formula P(R31)(R32)(R33), wherein R31, R32, and R33 have the meanings defined herein.


Radicals R31, R32, and R33 may independently represent identical or different organic radicals, for example hydrocarbyl radicals comprising 1 to 10 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, and t-butyl, aryl groups such as phenyl, o-tolyl, m-tolyl, p-tolyl, 1-naphthyl, or 2-naphthyl, or hydrocarbyl radicals comprising 1 to 20 carbon atoms, such as 1,1′-biphenol or 1,1′-binaphthol. The R31, R32, and R33 radicals may be connected to one another directly, meaning not solely via the central phosphorus atom. Alternatively, the R31, R32,and R33 radicals may be not directly connected to one another.


For example, R31, R32, and R33 may be selected from the group composed of phenyl, o-tolyl, m-tolyl, and p-tolyl. As another example, a maximum of two of the R31, R32, and R33 groups may be phenyl. Alternatively, a maximum of two of the R31, R32,and R33 groups may be o-tolyl.


Compounds of Formula IVa,

(o-tolyl-O—)w (m-tolyl-O—)x (p-tolyl-O—)y (phenyl-O—), P   Formula IVa

may be used as the monodentate P-containing ligand, wherein w, x, y, and z are integers, and the following conditions apply: w+x+y+z=3 and w, z≦2.


Examples of compounds of Formula IVa include (p-tolyl-O—)(phenyl-O—)2P, (m-tolyl-O—)(phenyl-O—)2P, (o-tolyl-O—)(phenyl-O—)2P, (p-tolyi-O—)2(phenyl-O—)P, (m-tolyl-O—)2(phenyl-O—)P, (o-tolyl-O—)2(phenyl-O—)P, (m-tolyl-O—)(p-tolyl-O—)(phenyl-O—)P, (o-tolyl-O—)(p-tolyl-O—)(phenyl-O—) P, (o-tolyl-O—)(m-tolyl-O—)(phenyl-O—)P, (p-tolyl-O—)3P, (m-tolyl-O—)(p-tolyl-O—)2P, (o-tolyl-O—)(p-tolyl-O—)2P, (m-tolyl-O—)2(p-tolyl-O—)P, (o-tolyl-O—)2(p-tolyl-O—)P, (o-tolyl-O—)(m-tolyl-O—)(p-tolyl-O—)P, (m-tolyl-O—)3P, (o-tolyl-O—)(m-tolyl-O—)2P, (o-tolyl-O—)2(m-tolyl-O—)P, or mixtures of such compounds.


Mixtures containing (m-tolyl-O—)3P, (m-tolyl-O—)2(p-tolyl-O—)P, (m-tolyl-O—)(p-tolyl-O—)2P, and (p-tolyl-O—)3P may be obtained, for example, by reacting a mixture containing m-cresol and pcresol, in particular in a molar ratio of 2:1 as occurs in the distillative processing of crude oil, with a phosphorus trihalide such as phosphorus trichloride.


Additional examples of monodentate P-containing ligands are the phosphites disclosed in U.S. Pat. No. 6,770,770 and referred to herein as phosphites of Formula IVb,

P(OR31)x (OR32)y (OR33)z (OR34)p   Formula IVb

wherein


R31 is an aromatic radical having a C1-C18 alkyl substituent in the o-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system, or having an aromatic substituent in the o-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system, or having an aromatic system fused on in the o-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system;


R32 is an aromatic radical having a C1-C18 alkyl substituent in the m-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system, or having an aromatic substituent in the m-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system, or having an aromatic system fused on in the m-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system, where the aromatic radical bears a hydrogen atom in the o-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system;


R33 is an aromatic radical having a C1-C18 alkyl substituent in the p-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system, or having an aromatic substituent in the p-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system, where the aromatic radical bears a hydrogen atom in the o-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system;


R34 is an aromatic radical which bears substituents other than those defined for R31, R32, and R33 in the o-, m-, and p-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system, where the aromatic radical bears a hydrogen atom in the o-position relative to the oxygen atom which connects the phosphorus atom to the aromatic system;


x is 1 or 2; and


y, z, and p independently of one another is 0, 1, or 2, provided that x+y+z+p=3.


Examples of radical R31 include o-tolyl, o-ethylphenyl, o-n-propylphenyl, o-isopropylphenyl, o-n-butylphenyl, o-sec-butylphenyl, o-tert-butylphenyl, (o-phenyl)-phenyl, or 1-naphthyl groups.


Examples of radical R32 include m-tolyl, m-ethylphenyl, m-n-propylphenyl, m-isopropylphenyl, m-n-butylphenyl, m-sec-butylphenyl, m-tert-butylphenyl, (m-phenyl)-phenyl, or 2-naphthyl groups.


Examples of radical R33 include p-tolyl, p-ethylphenyl, p-n-propylphenyl, p-isopropylphenyl, p-n-butylphenyl, p-sec-butylphenyl, p-tert-butylphenyl, or (p-phenyl)-phenyl groups.


Radical R34 may be, for example, phenyl, and p may be zero. The indices x, y, z, and p in compounds of Formula IVb may have the following possibilities:


















x
y
z
p









1
0
0
2



1
0
1
1



1
1
0
1



2
0
0
1



1
0
2
0



1
1
1
0



1
2
0
0



2
0
1
0



2
1
0
0










Preferred phosphites of Formula IVb are those in which p is zero, and R31, R32, and R33 are independently selected from o-isopropylphenyl, m-tolyl, and p-tolyl, and R34 is phenyl.


Additional examples of phosphites of Formula IVb are those in which R31 is the o-isopropylphenyl radical, R32 is the m-tolyl radical, and R33 is the p-tolyl radical, with the indices listed in the above table; also those in which R31 is the o-tolyl radical, R32 is the m-tolyl radical, and R33 is the p-tolyl radical, with the indices listed in the table; also those in which R31 is the 1-naphthyl radical, R32 is the m-tolyl radical, and R33 is the p-tolyl radical, with the indices listed in the table; also those in which R31 is the o-tolyl radical, R32 is the 2-naphthyl radical, and R33 is the p-tolyl radical, with the indices listed in the table; and lastly, those in which R31 is the o-isopropylphenyl radical, R32 is the 2-naphthyl radical, and R33 is the p-tolyl radical, with the indices listed in the table; and mixtures of these phosphites.


In one embodiment, the catalyst precursor composition may comprise a zero-valent nickel, at least one multidentate P-containing ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, a phosphine, and a mixed P-containing ligand or a combination of such members, and at least one monodentate P-containing ligand selected from tritolyl phosphite and phosphites of Formula IVb

P(OR31)x (OR32)y (OR33)z (OR34)p   Formula IVb

wherein R31, R32, and R33 are independently selected from o-isopropylphenyl, m-tolyl, and p-tolyl, R34 is phenyl, x is 1 or 2, and y, z, p are independently 0, 1, or 2, provided that x+y+z+p=3; and mixtures thereof.


A multidentate P-containing ligand may be suitable for use in the process of the invention if, as part of a catalyst precursor composition comprising a zero-valent nickel and the multidentate P-containing ligand, it can be used within a temperature range of about 80° C. to about 140° C., to produce a reaction mixture comprising 3PN and 2M3BN from a HCN-containing feed and a BD-containing feed. The multidentate P-containing ligand is suitable for use in the process of the invention in the case where the 2M3BN concentration of the reaction mixture comprising 3PN and 2M3BN can be maintained below about 15 weight percent of the total mass of the reaction mixture, for example at or below about 10 weight percent of the total mass of the reaction mixture, and the HCN conversion is about 95% or more. A catalyst precursor composition, comprising a P-containing ligand suitable for the process of the invention, may lack sufficient 3PN selectivity in BD hydrocyanation to produce a reaction mixture comprising 3PN and 2M3BN wherein the 2M3BN concentration is maintained below about 15 weight percent of the total mass of the reaction mixture. However, when used to hydrocyanate BD and to isomerize 2M3BN to 3PN concurrently in the same reaction zone, with a sufficient residence time, a catalyst precursor composition comprising a suitable P-containing ligand can produce a reaction mixture comprising 3PN and 2M3BN wherein the 2M3BN concentration is maintained below about 15 weight percent of the total mass of the reaction mixture. For the concurrent BD hydrocyanation/2M3BN isomerization process with a suitable multidentate P-containing ligand, the molar ratio of the HCN in the feed to the BD in the feed is in the range of about 0.90:1.00 to about 1.04:1.00. The molar ratio of the zero-valent nickel in the feed to the BD in the feed is in the range of about 0.00005:1.00 to about 0.0050:1.00. The mole ratio of multidentate P-containing ligand to zero-valent nickel is in the range of about 1/1 to about 6/1. Solvent, HCN, preparation of the catalyst precursor composition, reactor startup, and other operational information are as described for the process of the invention in other sections of this document.


The multidentate P-containing ligands useful in the catalyst precursor compositions employed in the present invention may be prepared by any suitable synthetic means known in the art, for example as described in at least some of the references cited as disclosing examples of multidentate P-containing ligands. For example, the multidentate P-containing ligands of Formula II and Formula III may be synthesized as described in U.S. Pat. Nos. 6,171,996 and 5,512,696, both of which are incorporated herein by reference. For example, the reaction of two equivalents of an ortho-substituted phenol with phosphorus trichloride gives the corresponding phosphorochloridite. The reaction of the phosphorochloridite with the desired substituted biphenol or octahydrobinaphthol in the presence of triethylamine gives the bidentate phosphite ligand. The crude bidentate phosphite ligand can be worked up by the process described in U.S. Pat. No. 6,069,267, which is incorporated herein by reference. As disclosed therein, the bidentate phosphite ligand product mixture can typically contain the desired product in about 70% to about 90% selectivity, with other phosphite by-products such as monodentate phosphites making up the balance of the product mixture. The bidentate phosphite ligand itself or these bidentate/monodentate phosphite ligand mixtures are suitable for use with the present invention.


The multidentate P-containing ligand itself or mixtures of the multidentate P-containing ligand and at least one monodentate P-containing ligand are suitable for use with the present invention.


The catalyst precursor compositions employed for this process should ideally be substantially free of carbon monoxide, oxygen, and water and may be preformed or prepared in situ according to techniques well known in the art. The catalyst precursor composition may be formed by contacting the multidentate P-containing ligand with a zero-valent nickel compound having ligands easily displaced by organophosphorus ligands, such as Ni(COD)2, Ni[P(O-o-C6H4CH3)3]3, and Ni[P(O-o-C6H4CH3)3]2(C2H4), all of which are well known in the art, wherein 1,5-cyclooctadiene (COD), tris(ortho-tolyl)phosphite [P(O-o-C6H4CH3)3], and ethylene (C2H4) are the easily displaced ligands. Elemental nickel, preferably nickel powder, when combined with a halogenated catalyst, as described in U.S. Pat. No. 3,903,120, is also a suitable source of zero-valent nickel. Alternatively, divalent nickel compounds can be combined with a reducing agent, to serve as a source of zero-valent nickel in the reaction, in the presence of the multidentate P-containing ligands. Suitable divalent nickel compounds include compounds of the formula NiZ2 where Z is halide, carboxylate, or acetylacetonate. Suitable reducing agents include metal borohydrides, metal aluminum hydrides, metal alkyls, Li, Na, K, Zn, Fe or H2. See, for example, U.S. Pat. No. 6,893,996. In the catalyst precursor composition, the multidentate P-containing ligand may be present in excess of what can theoretically be coordinated to the nickel at a given time.


The catalyst precursor composition may be dissolved in a solvent that is non-reactive toward, and miscible with, the hydrocyanation reaction mixture. Suitable solvents include, for example, aliphatic and aromatic hydrocarbons with 1 to 10 carbon atoms, and nitrile solvents such as acetonitrile. Alternatively, 3PN, a mixture of isomeric pentenenitriles, a mixture of isomeric methylbutenenitriles, a mixture of isomeric pentenenitriles and isomeric methylbutenenitriles, or the reaction product from a previous reaction campaign, may be used to dissolve the catalyst precursor composition.


The reaction temperature is maintained within the range of about 80° C. to about 140° C., for example within the range of about 100° C. to about 130° C. Generally, the reaction pressure should be sufficient to maintain the reagents in the liquid state, with such pressure at least, in part, a function of the amount of unreacted BD present in the reaction mixture. Though the invention is not limited by an upper limit of pressure, for practical purposes the pressure generally ranges from about 15 psia to about 300 psia (about 103 kPa to about 2068 kPa).


HCN, substantially free of carbon monoxide, oxygen, ammonia, and water can be introduced to the reaction as a vapor, liquid, or mixtures thereof. As an alternative, a cyanohydrin can be used as the source of HCN. See, for example, U.S. Pat. No. 3,655,723.


The molar ratio of the HCN in the feed to the BD in the feed is in the range of about 0.90:1.00 to about 1.04:1.00, for example in the range of about 0.92:1.00 to about 0.98:1.00. Avoiding the use of a large excess of BD in relation to HCN can be advantageous in that, after reaction, the small quantity of unreacted BD may not warrant recovery and recycle to the hydrocyanation reactor. Additionally, the formation of thermally-driven BD-based yield loss products, such as BD dimers, can be reduced with lower BD amounts.


The molar ratio of the zero-valent nickel in the feed to the BD in the feed is in the range of about 0.00005:1.00 to about 0.0050:1.00, for example in the range about 0.0001:1.00 to about 0.0010:1.00.


The residence time in the reaction zone (for example, the time necessary for the combined feeds to displace one reactor volume in a CSTR) is typically determined by the desire to maintain the 2M3BN concentration below about 15 weight percent of the reaction mass, for example at or below about 10 weight percent of the reaction mass, and is also related to the catalyst concentration and reaction temperature. Generally residence times will be in the range of about 0.5 to about 15 hours, for example in the range of about 1 to about 10 hours.


The hydrocyanation and isomerization reaction mixture may be used “as is” in subsequent reaction steps for the production of ADN. Alternatively, the reaction product and components of the catalyst precursor composition can be recovered by conventional techniques known in the art, such as, for example, by liquid-liquid extraction as disclosed in U.S. Pat. No. 6,936,171 and by flash distillation, for example at a pressure in the range of about 10 torr to about 700 torr (about 1 kPa to about 93 kPa). The catalyst precursor composition-containing “distillation tails” may be recycled back to the reaction zone after purging a portion of the mixture to prevent build-up of “high boiling” impurities. The reaction product, the “distillation make”, is a mixture comprised predominantly of 3PN, with lesser amounts of isomeric pentenenitriles, 2M3BN, 2-methyl-2-butenenitrile, BD, HCN, and vinylcyclohexene. The desired 3PN and other isomeric pentenenitriles can be recovered from the reaction product by distillation and other constituent parts such as BD, HCN, and 2M3BN either recycled to the reaction zone or disposed of.


The following Examples were performed using a catalyst precursor composition wherein the multidentate P-containing ligand was a bidentate P-containing ligand, referred to as “Phosphite A” in the chemical formula for the nickel source below. The multidentate P-containing ligand of the Examples is represented by Formula II wherein R1 is isopropyl; R2, R6, and R8 are H; and R3, R4, R5, and R7 are methyl. The nickel source charged to the autoclave comprised the compound (Phosphite A)Ni(crotyl)CN dissolved in a nitrile solvent mixture. “Crotyl” represents a butenyl group having the empirical formula C4H7.


The multidentate P-containing ligand, Phosphite A, of the Examples may be prepared by any suitable synthetic means known in the art. For example, 3,3′-diisopropyl-5,5′,6,6′-tetramethyl-2,2′-biphenol can be prepared by the procedure disclosed in United States Published Patent Application No.2003/0100802, which is incorporated herein by reference, in which 4-methylthymol can undergo oxidative coupling to the substituted biphenol in the presence of a copper chlorohydroxide-TMEDA complex (TMEDA is N,N,N′,N′-tetramethylethylenediamine) and air.


The phosphorochloridite of 2,4-xylenol, (C8H9O)2PCI, can be prepared, for example, by the procedure disclosed in United States Published Patent Application No. 2004/0106815, which is incorporated herein by reference. To form this phosphorochloridite selectively, anhydrous triethylamine and 2,4-xylenol can be added separately and concurrently in a controlled manner to PCI3 dissolved in an appropriate solvent under temperature-controlled conditions.


The reaction of the phosphorochloridite with the 3,3′-diisopropyl-5,5′,6,6′-tetramethyl-2,2′-biphenol to form the desired multidentate P-containing ligand, Phosphite A, can be performed, for example, according to the method disclosed in U.S. Pat. No. 6,069,267, which is hereby incorporated by reference. The phosphorochloridite can be reacted with 3,3′-diisopropyl-5,5′,6,6′-tetramethyl-2,2′-biphenol in the presence of an organic base to form Phosphite A, which can be isolated according to techniques well known in the art, as also described in U.S. Pat. No. 6,069,267.


For each Example, the (Phosphite A)Ni(crotyl)CN compound was prepared as follows. In a nitrogen atmosphere, the Phosphite A, represented by Formula II wherein R1 is isopropyl; R2, R6, and R8 are H; and R3, R4, R5, and R7 are methyl, and Ni(COD)2 (COD is 1,5-cyclooctadiene) were combined in a molar ratio of 1:1l in a flask. Trans-3-pentenenitrile (95 wt %, Aldrich), which had been previously dried over molecular sieves and degassed with nitrogen, was added to the same flask (about 200 mL for 10 g of Phosphite A) and the mixture was stirred until an orange homogeneous solution formed. All volatiles were removed under vacuum at ambient temperature to yield an orange powder. The powder was triturated with anhydrous acetonitrile to remove excess pentenenitriles and other impurities, and then all volatiles were again removed under vacuum to produce (Phosphite A)Ni(crotyl)CN as an orange solid.


Trans-3-pentenenitrile (95 wt %) produced from BD hydrocyanation, 2M3BN isomerization, and pentenenitrile hydrocyanation processes may be obtained commercially from the Sigma-Aldrich Chemical Company. This material contains trace amounts of 2M3BN also prepared from a BD hydrocyanation and/or 2M3BN isomerization process.


The purity of the BD feed was greater than 99%. Freshly prepared anhydrous, uninhibited, liquid HCN was utilized in all Examples.


Embodiments falling within the scope of the present invention may be further understood in view of the following non-limiting examples.


EXAMPLES
Example 1

The reaction was carried out in a 100 mL autoclave fitted with a magnetically driven stirrer and dip legs for the addition of feeds. The reactor was operated liquid full, which resulted in a working volume of 118 mL. The reaction temperature was maintained at 120° C. by means of a combination of electrical heating on the outside and passing coolant through an internal coil. Pressure in the reactor was controlled by a manual back-pressure regulator at 130 psia (896 kPa). The exit tube continuously fed a flash-distillation column, which operated under reduced pressure (100 torr; 13.3 kPa) to separate reaction products from the catalyst.


A catalyst precursor composition solution comprised of (Phosphite A)Ni(crotyl)CN (2.5 wt %) ,1.6 wt % Phosphite A, and 1.2 wt % Phosphite A oxides, 3PN (82 wt %), 2PN (0.9 wt %), 4PN (1.2 wt %), 2M3BN (1.4 wt %), 2-methyl-2-butenenitriles (2M2BN, 0.7 wt %), dimethylsuccinonitrile (1.0 wt %), MGN (3.5 wt %), and ADN (2.4 wt %), was fed continuously and concurrently with BD and HCN to the autoclave such that the molar ratio of Ni:HCN:BD fed was about 0.00046:0.963:1.0 and the total flow rates were such that the residence time in the reactor was about 3.4 hours. Flows were maintained for 24 hours in order to approach a steady state condition. Samples were periodically drawn from the line exiting the reactor and analyzed by both high-pressure liquid chromatography (HPLC) for catalyst and by gas chromatography (GC) for nitrile products and byproducts. The 2M3BN was analyzed at 6.6 wt % of the reaction mixture. 92.9% of the BD and 96.5% of the HCN fed to the autoclave was converted into useful products comprised of 2PN, 3PN, 4PN, and 2M3BN. Of the total moles of BD converted, the selectivity to these useful products was 96.7%.


Example 2

The reaction was carried out in a 1 liter autoclave fitted with a magnetically driven stirrer and dip legs for the addition of feeds and removal of product. The product removal dip leg was adjusted to provide a working volume of 750 mL. The reaction temperature was maintained at 110° C. by means of a combination of electrical heating on the outside and passing coolant through an internal coil. Pressure in the reactor was controlled by a manual back-pressure regulator at 100 psia (689 kPa). The exit tube continuously fed a flash-distillation column, which operated under reduced pressure (300 torr; 40 kPa) to separate reaction products from the catalyst.


A catalyst precursor composition solution comprised of (Phosphite A)Ni(crotyl)CN (2.8 wt %) , 2.1 wt % Phosphite A, and 1.4 wt % Phosphite A oxides, 3PN (83 wt %), 2PN (6.1 wt %), 4PN (0.8 wt %), 2M3BN (1.4 wt %), 2M2BN (0.9 wt %), dimethylsuccinonitrile (1.0 wt %), MGN (0.2 wt %), and ADN (1.7 wt %), was fed continuously and concurrently with BD and HCN to the autoclave such that the molar ratio of Ni:HCN:BD fed was about 0.00055:0.946:1.0 and the total flow rates were such that the residence time in the reactor was about 7.3 hours. Flows were maintained for 40 hours in order to approach a steady state condition. Samples were periodically drawn from the line exiting the reactor and analyzed by both HPLC for catalyst and by GC for nitrile products and byproducts. The 2M3BN was analyzed at 6.6 wt % of the reaction mixture. 91.1% of the BD and 96.3% of the HCN fed to the autoclave was converted into useful products comprised of 2PN, 3PN, 4PN, and 2M3BN. Of the total moles of BD converted, the selectivity to these useful products was 96.1%.


Example 3

The reaction was carried out in a 1 liter autoclave fitted with a magnetically driven stirrer and dip legs for the addition of feeds and extraction of product. The product removal dip leg was adjusted to provide a working volume of 750 mL. The reaction temperature was maintained at 120° C. by means of a combination of electrical heating on the outside and passing coolant through an internal coil. Pressure in the reactor was controlled by a manual back-pressure regulator at 100 psia (689 kPa). The exit tube continuously fed a flash-distillation column, which operated under reduced pressure (300 torr; 40 kPa) to separate reaction products from the catalyst.


A catalyst precursor composition solution comprised of (Phosphite A)Ni(crotyl)CN (2.8 wt %) , 2.1 wt % Phosphite A, and 1.4 wt % Phosphite A oxides, 3PN (83 wt %), 2PN (6.1 wt %), 4PN (0.8 wt %), 2M3BN (1.4 wt %), 2M2BN (0.9 wt %), dimethylsuccinonitrile (1.0 wt %), MGN (0.2 wt %), and ADN (1.7 wt %), was fed continuously and concurrently with BD and HCN to the autoclave such that the molar ratio of Ni:HCN:BD fed was about 0.00025:0.948:1.0 and the total flow rates were such that the residence time in the reactor was about 8.2 hours. Flows were maintained for 40 hours in order to approach a steady state condition. Samples were periodically drawn from the line exiting the reactor and analyzed by both HPLC for catalyst and by GC for nitrile products and byproducts. The 2M3BN was analyzed at 10.3 wt % of the reaction mixture. 90.9% of the BD and 96.9% of the HCN fed to the autoclave was converted into useful products comprised of 2PN, 3PN, 4PN, and 2M3BN. Of the total moles of BD converted, the selectivity to these useful products was 96.5%.


Example 4

The reaction was carried out in a 1 liter autoclave fitted with a magnetically driven stirrer and dip legs for the addition of feeds and extraction of product. The product removal dip leg was adjusted to provide a working volume of 750 mL. The reaction temperature was maintained at 130° C. by means of a combination of electrical heating on the outside and passing coolant through an internal coil. Pressure in the reactor was controlled by a manual back-pressure regulator at 100 psia (689 kPa). The exit tube continuously fed a flash-distillation column, which operated under reduced pressure (300 torr; 40 kPa) to separate reaction products from the catalyst.


A catalyst precursor composition solution comprised of (Phosphite A)Ni(crotyl)CN (2.8 wt %) , 2.1 wt % Phosphite A, and 1.4 wt % Phosphite A oxides, 3PN (83 wt %), 2PN (6.1 wt %), 4PN (0.8 wt %), 2M3BN (1.4 wt %), 2M2BN (0.9 wt %), dimethylsuccinonitrile (1.0 wt %), MGN (0.2 wt %), and ADN (1.7 wt %), was fed continuously and concurrently with BD and HCN to the autoclave such that the molar ratio of Ni:HCN:BD fed was about 0.00035:0.925:1.0 and the total flow rates were such that the residence time in the reactor was about 2.0 hours. Flows were maintained for 12 hours in order to approach a steady state condition. Samples were periodically drawn from the line exiting the reactor and analyzed by both HPLC for catalyst and by GC for nitrile products and byproducts. The 2M3BN was analyzed at 12.4 wt % of the reaction mixture. 89.1% of the BD and 96.3% of the HCN fed to the autoclave was converted into useful products comprised of 2PN, 3PN, 4PN, and 2M3BN. Of the total moles of BD converted, the selectivity to these useful products was 96.7%.


Although particular embodiments of the present invention have been described in the foregoing description, it will be understood by those skilled in the art that the invention is capable of numerous modifications, substitutions and rearrangements without departing from the spirit or essential attributes of the invention. Reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

Claims
  • 1. A process for the continuous production of 3-pentenenitrile, comprising: (a) continuously introducing feed comprising hydrogen cyanide, 1,3-butadiene, and a catalyst precursor composition to a reaction zone, wherein the molar ratio of the hydrogen cyanide in the feed to the 1,3-butadiene in the feed is in the range of about 0.90:1.00 to about 1.04:1.00, and wherein the catalyst precursor composition comprises a zero-valent nickel and at least one multidentate phosphorus-containing ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, a phosphine, and a mixed phosphorus-containing ligand or a combination of such members;(b) displacing a product mixture from the reaction zone by the feed which is continuously introduced into the reaction zone; and(c) maintaining a residence time in the reaction zone sufficient to convert about 95% or more of the hydrogen cyanide and to produce the product mixture, wherein the product mixture comprises 3-pentenenitrile and 2-methyl-3-butenenitrile, and wherein the 2-methyl-3-butenenitrile concentration is maintained below about 15 weight percent of the total mass of the product mixture.
  • 2. The process according to claim 1, wherein the molar ratio of the zero-valent nickel in the feed to the 1,3-butadiene in the feed is in the range of about 0.00005:1.00 to about 0.0050:1.00.
  • 3. The process according to claim 1, wherein the temperature is maintained within a range of about 80° C. to about 140° C.
  • 4. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a phosphite.
  • 5. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a phosphonite.
  • 6. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a phosphinite.
  • 7. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a phosphine.
  • 8. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a mixed phosphorus-containing ligand comprising at least one combination selected from the group consisting of a phosphite-phosphonite, a phosphite-phosphinite, a phosphite-phosphine, a phosphonite-phosphinite, a phosphonite-phosphine, and a phosphinite-phosphine or a combination of such members.
  • 9. The process according to claim 1, wherein the temperature is maintained within the range of about 100° C. to about 130° C.
  • 10. The process according to claim 1, wherein the molar ratio of the hydrogen cyanide in the feed to the butadiene in the feed is in the range of about 0.92:1.00 to about 0.98:1.00.
  • 11. The process according to claim 1, wherein the molar ratio of the zero-valent nickel in the feed to the butadiene in the feed is in the range of about 0.0001:1.00 to about 0.0010:1.00.
  • 12. The process according to claim 1, wherein the residence time in the reaction zone is sufficient to maintain the 2-methyl-3-butenenitrile concentration at or below about 10 weight percent of the total mass of the product mixture.
  • 13. The process according to claim 1, wherein said feed comprises 2-methyl-3-butenenitrile.
  • 14. The process according to claim 1, wherein the catalyst precursor composition further comprises at least one monodentate phosphorus-containing ligand selected from the group consisting of a phosphite, a phosphonite, a phosphinite, and a phosphine or a combination of such members.
  • 15. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a bidentate phosphite.
  • 16. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a bidentate phosphonite.
  • 17. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a bidentate phosphinite.
  • 18. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a bidentate phosphine.
  • 19. The process according to claim 1, wherein the multidentate phosphorus-containing ligand is a bidentate mixed phosphorus-containing ligand selected from the group consisting of a phosphite-phosphonite, a phosphite-phosphinite, a phosphite-phosphine, a phosphonite-phosphinite, a phosphonite-phosphine, and a phosphinite-phosphine or a combination of such members.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of priority from Provisional Application No. 60/830,970, filed Jul. 14, 2006. This application hereby incorporates by reference Provisional Application No. 60/830,970 in its entirety. This application relates to commonly-assigned applications filed concurrently on Jul. 12, 2007.

US Referenced Citations (172)
Number Name Date Kind
2768132 Halliwell Oct 1956 A
3370082 Eisfeld et al. Feb 1968 A
3496215 Drinkard et al. Feb 1970 A
3496217 Drinkard, Jr. et al. Feb 1970 A
3496218 Drinkard, Jr. Feb 1970 A
3522288 Drinkard, Jr. et al. Jul 1970 A
3536748 Drinkard, Jr. et al. Oct 1970 A
3551474 Drinkard et al. Dec 1970 A
3564040 Downing et al. Feb 1971 A
3579560 Drinkard et al. May 1971 A
3655723 Drinkard, Jr. Apr 1972 A
3694485 Drinkard, Jr. et al. Sep 1972 A
3752839 Drinkard, Jr. et al. Aug 1973 A
3766231 Gosser et al. Oct 1973 A
3766237 Chia et al. Oct 1973 A
3766241 Drinkard, Jr. et al. Oct 1973 A
3773809 Walter Nov 1973 A
3775461 Drinkard, Jr. et al. Nov 1973 A
3798256 King et al. Mar 1974 A
3818067 Downing et al. Jun 1974 A
3818068 Wells Jun 1974 A
3846474 Mok Nov 1974 A
3849472 Waddan Nov 1974 A
3850973 Seidel et al. Nov 1974 A
3853754 Gosser Dec 1974 A
3853948 Drinkard, Jr. et al. Dec 1974 A
3864380 King et al. Feb 1975 A
3869501 Waddan Mar 1975 A
3903120 Shook, Jr. et al. Sep 1975 A
3920721 Gosser Nov 1975 A
3927056 Gosser Dec 1975 A
3947487 Crooks Mar 1976 A
4045495 Nazarenko et al. Aug 1977 A
4046815 Nazarenko Sep 1977 A
4076756 Nazarenko et al. Feb 1978 A
4087452 Kuntz May 1978 A
4146555 Kershaw Mar 1979 A
4147717 Kershaw Apr 1979 A
4177215 Seidel Dec 1979 A
4210558 Crooks Jul 1980 A
4230634 Benzie et al. Oct 1980 A
4240976 Benzie et al. Dec 1980 A
4251468 Nazarenko Feb 1981 A
4298546 McGill Nov 1981 A
4328172 Rapoport May 1982 A
4330483 Rapoport May 1982 A
4339395 Barnette et al. Jul 1982 A
4371474 Rapoport Feb 1983 A
4382038 McGill May 1983 A
4385007 Shook, Jr. May 1983 A
4416824 Reimer et al. Nov 1983 A
4416825 Ostermaier Nov 1983 A
4434316 Barnette Feb 1984 A
4539302 Leyendecker et al. Sep 1985 A
4705881 Rapoport Nov 1987 A
4749801 Bealty et al. Jun 1988 A
4774353 Hall et al. Sep 1988 A
4874884 McKinney et al. Oct 1989 A
4990645 Back et al. Feb 1991 A
5107012 Grunewald Apr 1992 A
5302756 McKinney Apr 1994 A
5312959 Sieja et al. May 1994 A
5449807 Druliner Sep 1995 A
5488129 Huser et al. Jan 1996 A
5512695 Kreutzer et al. Apr 1996 A
5512696 Kreutzer et al. Apr 1996 A
5523453 Breikss Jun 1996 A
5543536 Tam Aug 1996 A
5663369 Kreutzer et al. Sep 1997 A
5688986 Tam et al. Nov 1997 A
5693843 Breikss et al. Dec 1997 A
5696280 Shapiro Dec 1997 A
5709841 Reimer Jan 1998 A
5723641 Tam et al. Mar 1998 A
5773637 Cicha et al. Jun 1998 A
5821378 Foo et al. Oct 1998 A
5847191 Bunel et al. Dec 1998 A
5856555 Huser et al. Jan 1999 A
5908805 Huser et al. Jun 1999 A
5959135 Garner et al. Sep 1999 A
5981722 Chen et al. Nov 1999 A
6020516 Foo et al. Feb 2000 A
6069267 Tam May 2000 A
6090987 Billig et al. Jul 2000 A
6121184 Druliner et al. Sep 2000 A
6127567 Garner et al. Oct 2000 A
6147247 Voit et al. Nov 2000 A
6169198 Fischer et al. Jan 2001 B1
6171996 Garner et al. Jan 2001 B1
6171997 Foo et al. Jan 2001 B1
6197992 Fischer et al. Mar 2001 B1
6242633 Fischer et al. Jun 2001 B1
6284865 Tam et al. Sep 2001 B1
6307109 Kanel et al. Oct 2001 B1
6355833 Fischer et al. Mar 2002 B2
6461481 Barnette et al. Oct 2002 B1
6469194 Burattin et al. Oct 2002 B2
6521778 Fischer et al. Feb 2003 B1
6646148 Kreutzer et al. Nov 2003 B1
6660877 Lenges et al. Dec 2003 B2
6737539 Lenges et al. May 2004 B2
6753440 Druliner et al. Jun 2004 B2
6770770 Baumann et al. Aug 2004 B1
6846945 Lenges et al. Jan 2005 B2
6852199 Jungkamp et al. Feb 2005 B2
6855799 Tam et al. Feb 2005 B2
6893996 Chu et al. May 2005 B2
6897329 Jackson et al. May 2005 B2
6924345 Gagne et al. Aug 2005 B2
6936171 Jackson et al. Aug 2005 B2
6984604 Cobb et al. Jan 2006 B2
7022866 Bartsch et al. Apr 2006 B2
7067685 Bartsch et al. Jun 2006 B2
7084293 Rosier et al. Aug 2006 B2
7084294 Jungkamp et al. Aug 2006 B2
7098358 Burattin et al. Aug 2006 B2
7105696 Burattin et al. Sep 2006 B2
7253298 Galland et al. Aug 2007 B2
7345006 Bartsch et al. Mar 2008 B2
7381845 Weiskopf et al. Jun 2008 B2
7439381 Jungkamp et al. Oct 2008 B2
7442825 Galland et al. Oct 2008 B2
7470805 Rosier et al. Dec 2008 B2
7521575 Bartsch et al. Apr 2009 B2
7528275 Bartsch et al. May 2009 B2
7538240 Jungkamp et al. May 2009 B2
7541486 Scheidel et al. Jun 2009 B2
7700795 Haderlein et al. Apr 2010 B2
20030023110 Tam et al. Jan 2003 A1
20030100802 Shapiro May 2003 A1
20030135014 Radu et al. Jul 2003 A1
20030212298 Brasse et al. Nov 2003 A1
20040063991 Burattin et al. Apr 2004 A1
20040106815 Ritter Jun 2004 A1
20040176622 Bartsch et al. Sep 2004 A1
20040235648 Bartsch et al. Nov 2004 A1
20040260112 Basset et al. Dec 2004 A1
20050090677 Bartsch et al. Apr 2005 A1
20050090678 Bartsch et al. Apr 2005 A1
20050247624 Jungkamp et al. Nov 2005 A1
20060142609 Bourgeois et al. Jun 2006 A1
20060175189 Gerber et al. Aug 2006 A1
20060252955 Rosier et al. Nov 2006 A1
20060258873 Rosier et al. Nov 2006 A1
20060258874 Bartsch et al. Nov 2006 A1
20060264651 Bartsch et al. Nov 2006 A1
20070060766 Bartsch et al. Mar 2007 A1
20070073071 Haderlein et al. Mar 2007 A1
20070083057 Haderlein et al. Apr 2007 A1
20070088173 Haderlein et al. Apr 2007 A1
20070112215 Jungkamp et al. May 2007 A1
20070155977 Jungkamp et al. Jul 2007 A1
20070155978 Jungkamp et al. Jul 2007 A1
20070155980 Scheidel et al. Jul 2007 A1
20070115936 Haderlein et al. Oct 2007 A1
20080015378 Foo et al. Jan 2008 A1
20080015380 Foo et al. Jan 2008 A1
20080015381 Foo et al. Jan 2008 A1
20080015382 Foo et al. Jan 2008 A1
20080071105 Bartsch et al. Mar 2008 A1
20080076944 Bartsch et al. Mar 2008 A1
20080083607 Deckert et al. Apr 2008 A1
20080221351 Bartsch et al. Sep 2008 A1
20080227214 Jungkamp et al. Sep 2008 A1
20080227998 Scheidel et al. Sep 2008 A1
20080242883 Jungkamp et al. Oct 2008 A1
20080242885 Jungkamp et al. Oct 2008 A1
20080242886 Bartsch et al. Oct 2008 A1
20080275266 Bartsch et al. Nov 2008 A1
20080281119 Scheidel et al. Nov 2008 A1
20080281120 Jungkamp et al. Nov 2008 A1
20090054671 Haderlein et al. Feb 2009 A1
Foreign Referenced Citations (213)
Number Date Country
6522096 Feb 1997 AU
199665220 Feb 1997 AU
1324613 Nov 1993 CA
2462720 Apr 2003 CA
2552862 Aug 2005 CA
1535179 Oct 2004 CN
1807088 Mar 1960 DE
1807088 Jun 1969 DE
2055747 May 1971 DE
1593277 Aug 1973 DE
1593277 Mar 1974 DE
2700904 Oct 1983 DE
68909466 Mar 1994 DE
10136488 Feb 2003 DE
10150285 Apr 2003 DE
10350999 Jun 2005 DE
102004004696 Aug 2005 DE
0001899 Mar 1982 EP
123438 Jul 1987 EP
160296 Oct 1988 EP
268448 Sep 1991 EP
510689 Oct 1992 EP
248643 Mar 1993 EP
336314 Sep 1993 EP
464691 Dec 1993 EP
675871 Apr 1997 EP
634395 Sep 1997 EP
650959 Sep 1997 EP
784610 Feb 1999 EP
757672 Jun 1999 EP
792259 Aug 1999 EP
804412 Dec 1999 EP
1000019 May 2000 EP
1001928 May 2000 EP
1003716 May 2000 EP
1019190 Jul 2000 EP
755302 Oct 2000 EP
929513 Apr 2001 EP
881924 May 2001 EP
854858 Jun 2001 EP
815073 Jul 2001 EP
1144114 Sep 2001 EP
1091804 Feb 2002 EP
944585 Apr 2002 EP
1000019 Feb 2003 EP
911339 Apr 2003 EP
1216268 Nov 2003 EP
1350788 Nov 2003 EP
1003607 Dec 2003 EP
1003716 Feb 2004 EP
1313743 Mar 2004 EP
1414567 May 2004 EP
1427695 Jun 2004 EP
1438133 Jul 2004 EP
1019190 Dec 2004 EP
1140801 Feb 2005 EP
1395547 Mar 2005 EP
1001928 Apr 2005 EP
1521736 Apr 2005 EP
1521737 Apr 2005 EP
1521738 Apr 2005 EP
1603865 Dec 2005 EP
1324976 Feb 2006 EP
1214975 Mar 2006 EP
1324978 Mar 2006 EP
1648860 Apr 2006 EP
891323 Jun 2006 EP
1226147 Jun 2006 EP
1438317 Jun 2006 EP
1682561 Jul 2006 EP
1448668 Aug 2006 EP
1587621 Aug 2006 EP
1713759 Oct 2006 EP
1713761 Oct 2006 EP
1713762 Oct 2006 EP
1713766 Oct 2006 EP
1716102 Nov 2006 EP
1716103 Nov 2006 EP
1716104 Nov 2006 EP
1716105 Nov 2006 EP
1716106 Nov 2006 EP
1716107 Nov 2006 EP
1716109 Nov 2006 EP
1610893 Mar 2007 EP
1621531 Mar 2007 EP
1438132 Apr 2007 EP
1799697 Jun 2007 EP
1713764 Aug 2007 EP
1713816 Aug 2007 EP
1825914 Aug 2007 EP
1448620 Jun 2008 EP
1817108 Jun 2008 EP
1713760 Jul 2008 EP
1571172 Oct 2008 EP
1988998 Nov 2008 EP
1265832 May 2009 EP
1592659 Jul 2009 EP
1586598 Sep 2009 EP
2098106 Sep 2009 EP
1567478 Oct 2009 EP
1682559 Dec 2009 EP
1630166 Feb 2010 EP
1544656 Nov 1968 FR
2015115 Apr 1970 FR
1603513 May 1971 FR
2069411 Sep 1971 FR
2845379 Dec 2004 FR
2873696 Feb 2006 FR
2873696 Oct 2006 FR
0219474 Jul 1924 GB
1104140 Feb 1968 GB
1203702 Sep 1970 GB
1213175 Nov 1970 GB
1429169 Mar 1976 GB
1429621 Mar 1976 GB
1436932 May 1976 GB
1458322 Dec 1976 GB
1482909 Aug 1977 GB
2007521 May 1979 GB
1565443 Apr 1980 GB
1594694 Aug 1981 GB
2007521 Jun 1982 GB
60044295 Mar 1985 JP
1136333 Sep 1989 JP
7188144 Jul 1995 JP
2004PA002764 Jun 2004 MX
WO7900193 Apr 1979 WO
WO9414752 Jul 1994 WO
WO9514659 Jun 1995 WO
WO9528228 Oct 1995 WO
WO9529153 Nov 1995 WO
WO9611182 Apr 1996 WO
WO9616022 May 1996 WO
WO9622968 Aug 1996 WO
WO9629303 Sep 1996 WO
WO9703040 Jan 1997 WO
WO9712857 Apr 1997 WO
WO9724183 Jul 1997 WO
WO9736855 Oct 1997 WO
WO9811051 Mar 1998 WO
WO9827054 Jun 1998 WO
WO9906146 Feb 1999 WO
WO9906356 Feb 1999 WO
WO9906359 Feb 1999 WO
WO9913983 Mar 1999 WO
WO9952632 Oct 1999 WO
WO9964155 Dec 1999 WO
WO0001485 Jan 2000 WO
WO0037431 Jun 2000 WO
WO0121684 Mar 2001 WO
WO0136429 May 2001 WO
WO0168247 Sep 2001 WO
WO0211108 Feb 2002 WO
WO0213964 Feb 2002 WO
WO0218392 Mar 2002 WO
WO0226698 Apr 2002 WO
WO0230854 Apr 2002 WO
WO02053527 Jul 2002 WO
WO02092551 Nov 2002 WO
WO03011457 Feb 2003 WO
WO03018540 Mar 2003 WO
WO03024919 Mar 2003 WO
WO03031392 Apr 2003 WO
WO03033141 Apr 2003 WO
WO03033509 Apr 2003 WO
WO03046019 Jun 2003 WO
WO03046049 Jun 2003 WO
WO03068729 Aug 2003 WO
WO03076394 Sep 2003 WO
WO2004007431 Jan 2004 WO
WO2004007432 Jan 2004 WO
WO2004007435 Jan 2004 WO
WO2004007508 Jan 2004 WO
WO0168247 Jun 2004 WO
WO2004060855 Jul 2004 WO
WO2004064994 Aug 2004 WO
WO2004065352 Aug 2004 WO
WO2004080924 Sep 2004 WO
WO2004080948 Sep 2004 WO
WO2004087314 Oct 2004 WO
WO2005019160 Mar 2005 WO
WO2005042547 May 2005 WO
WO2005042156 May 2005 WO
WO2005042157 May 2005 WO
WO2005042547 May 2005 WO
WO2005042549 May 2005 WO
WO 2005073170 Aug 2005 WO
WO 2005073173 Aug 2005 WO
WO2005073167 Aug 2005 WO
WO2005073168 Aug 2005 WO
WO2005073169 Aug 2005 WO
WO2005073170 Aug 2005 WO
WO2005073171 Aug 2005 WO
WO2005073172 Aug 2005 WO
WO2005073173 Aug 2005 WO
WO2005073174 Aug 2005 WO
WO2005073175 Aug 2005 WO
WO2005073176 Aug 2005 WO
WO2005073178 Aug 2005 WO
WO2005073179 Aug 2005 WO
WO2005073241 Aug 2005 WO
WO2006040023 Apr 2006 WO
WO2006042675 Apr 2006 WO
WO2005073166 Mar 2007 WO
WO2007051374 May 2007 WO
WO2007096274 Aug 2007 WO
WO2007115936 Oct 2007 WO
WO2008008926 Jan 2008 WO
WO2008008928 Jan 2008 WO
WO2008008929 Jan 2008 WO
WO2008008930 Jan 2008 WO
WO2008028843 Mar 2008 WO
WO2008062058 May 2008 WO
Related Publications (1)
Number Date Country
20080015380 A1 Jan 2008 US
Provisional Applications (1)
Number Date Country
60830970 Jul 2006 US